Tuberin, the Tsc2 gene product, integrates the phosphatidylinositol 3-kinase/mitogen-activated protein kinase (mitogenic) and LKB1/AMP-activated protein kinase (AMPK; energy) signaling pathways, and previous independent studies have shown that loss of tuberin is associated with elevated AMPK signaling and altered p27 function. In Tsc2-null tumors and tumor-derived cells from Eker rats, we observed elevated AMPK signaling and concordant cytoplasmic mislocalization of p27. Cytoplasmic localization of p27 in Tsc2-null cells was reversible pharmacologically using inhibitors of the LKB1/ AMPK pathway, and localization of p27 to the cytoplasm could be induced directly by activating AMPK physiologically (glucose deprivation) or genetically (constitutively active AMPK) in Tsc2-proficient cells. Furthermore, AMPK phosphorylated p27 in vitro on at least three sites including T170 near the nuclear localization signal, and T170 was shown to determine p27 localization in response to AMPK signaling. p27 functions in the nucleus to suppress cyclin-dependent kinase-2 (Cdk2) activity and has been reported to mediate an antiapoptotic function when localized to the cytoplasm. We found that cells with elevated AMPK signaling and cytoplasmic p27 localization exhibited elevated Cdk2 activity, which could be suppressed by inhibiting AMPK signaling. In addition, cells with elevated AMPK signaling and cytoplasmic p27 localization were resistant to apoptosis, which could be overcome by inhibition of AMPK signaling and relocalization of p27 to the nucleus. These data show that AMPK signaling determines the subcellular localization of p27, and identifies loss of integration of pathways controlling energy balance, the cell cycle, and apoptosis due to aberrant AMPK and p27 function as a feature of cells that have lost the Tsc2 tumor suppressor gene. [Cancer Res 2008;68(16):6496-506] 
Introduction
Tuberous sclerosis complex (TSC) is an autosomal dominant hereditary syndrome leading to the development of hamartomas in several organs including the brain, skin, kidney, heart, and lungs (1) . Inactivating mutations in either the TSC1 gene or the TSC2 gene encoding hamartin and tuberin, respectively, cause TSC, and loss of heterozygosity for either TSC1 or TSC2 is a common occurrence in hamartomas of patients with TSC (1) . At the molecular level, tuberin interacts with hamartin and functions as a GTPase activating protein for the small GTPase Ras homology enriched in brain (Rheb; refs. 1, 2). This tuberin-mediated decrease in Rheb-GTP levels inactivates mammalian target of rapamycin (mTOR) signaling, which leads to inactivation of ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E binding protein 1, resulting in decreased protein synthesis and cell growth (3) .
Tuberin is phosphorylated by AKT in response to phosphatidylinositol 3-kinase (PI3K) signaling, and this phosphorylation inhibits tuberin-mediated repression of Rheb, activating mTOR signaling to increase protein synthesis (2) . In addition, loss of tuberin and the subsequent increase in S6K activity have been reported to lead to an autoregulatory negative feedback loop that inhibits PI3K signaling because S6K phosphorylates and inhibits insulin receptor substrate 1 (IRS1; refs. [4] [5] [6] . Additionally, loss of Tsc1/Tsc2 impairs AKT signaling through platelet-derived growth factor receptor and epidermal growth factor receptor downregulation (7) . Tuberin is also phosphorylated by AMP-activated protein kinase (AMPK), a heterotrimeric protein complex that responds to changes in cellular AMP/ATP ratios to regulate energyconsuming (anabolic) and energy-generating (catabolic) processes (8, 9) . Phosphorylation of tuberin by AMPK enhances tuberin repression of mTOR signaling, and tuberin is essential for altered cell growth in response to energy deprivation (9) . Thus, tuberin functions in the cell as a rheostat to integrate the mitogenic and energy-sensing pathways.
In addition to regulating cell growth via mTOR signaling, tuberin is also thought to influence both the protein levels and subcellular localization of p27 (10) . p27 is a member of the Cip/Kip family of cyclin-dependent kinase (Cdk) inhibitors that functions to negatively regulate cyclin A-Cdk2 and cyclin E-Cdk2 complexes in the nucleus, preventing cell cycle progression (11) . p27 stability and localization are regulated primarily by phosphorylation, which can target p27 for proteosome degradation or promote interaction with 14-3-3 and lead to cytoplasmic retention of this Cdk inhibitor (10) . In addition, p27 degradation is mediated by different processes in the cytosol and nucleus, potentially contributing to selective cytoplasmic or nuclear accumulation (12) . Cells lacking tuberin have been reported to exhibit reduced p27 expression in some cases and cytoplasmic mislocalization of p27 in others. Tuberin has also been reported to directly interact with p27 to regulate p27 interaction with 14-3-3 and the Skp1/cullin/F-box protein complex, an E3 ubiquitin ligase involved in targeting p27 for degradation (13) (14) (15) . However, an understanding of sometimes discordant findings on p27 expression in Tsc2-null cells as well as a mechanistic basis for modulation of p27 function in these cells has been elusive.
Loss of AKT activity was recently found to activate AMPK via modulation of AMP levels, and AMPK activity is elevated in Tsc2 À/À mouse embryonic fibroblasts (MEF; ref. 16 ). This suggests that elevated AMPK signaling may be a consistent feature of tuberinnull cells due to the aforementioned negative feedback loop that represses AKT in these cells. In addition, AMPK signaling was recently found to phosphorylate p27 and regulate p27 protein levels (17) , leading us to hypothesize that AMPK signaling could be responsible for altered p27 localization and activity in tuberin-null cell lines and tumors.
Using a rat model for Tsc2 deficiency, we found that tumors and tumor-derived cell lines lacking tuberin had activated AMPK and exhibited cytoplasmic localization of p27. Furthermore, modulation of AMPK signaling was shown to directly control subcellular localization of p27 independent of tuberin expression due, in part, to phosphorylation of p27 at T170. In addition, tuberin-null tumors and cell lines with constitutively activated AMPK exhibited increased Cdk2 activity and resistance to apoptosis, which were overcome by inhibition of AMPK signaling and relocalization of p27 to the nucleus. (7). Plasmid preparation and transfection. The Flag-p27-wild-type (WT) construct was generated by subcloning a PCR product generated from rat p27 cDNA into the pCMV-Tag2-Flag expression vector (Stratagene). The glutathione S-transferase (GST)-p27-WT construct was generated by digesting the p27 coding sequence from Flag-p27-WT and ligating it into pGEX-6P-1. Mutagenesis was done using the QuickChange XL site-directed mutagenesis kit (Stratagene). AMPK-a constructs (9) were a gift of Drs. S. Fischer (Department of Carcinogenesis, University of Texas M. D. Anderson Cancer Center, Smithville, TX) and K. Guan (Department of Pharmacology, University of California, San Diego, CA). Transient transfections were done using Lipofectamine 2000 (Invitrogen) and Effectene (Qiagen).
Materials and Methods
Subcellular fractionation. Subcellular fractionation of cells to yield nuclear and cytosolic fractions was done as previously described (22) . Briefly, cells were resuspended in hypotonic buffer and disrupted with a Dounce homogenizer and the crude nuclei pelleted by centrifugation. The supernatant was collected as the cytosolic fraction and the crude nuclei were further purified to yield the nuclear fraction.
Antibodies and reagents. The following antibodies and reagents were used: tuberin (Epitomics); Cdk2 (Santa Cruz Biotechnology, Inc.); AMPK-a1 and AMPK-a2 (Abcam); p27 (K5020; BD Transduction Laboratories); Sp1 (Upstate Biotechnology); AMPK-a, phospho-AMPK-a (T172), acetyl-CoA carboxylase (ACC), phospho-ACC (S79), S6, and phosho-S6 (Cell Signaling Technology); and Compound C and H-89 (Calbiochem). A, left, whole-cell, cytosolic, and nuclear lysates generated from the tuberin-null ELT-3 cell line and NIH3T3 cells were immunoblotted with anti-p27 and anti-Sp1 antibodies. Right, ELT-3 and NIH3T3 cells were also examined by immunocytochemistry with an anti-p27 antibody (original magnification, Â40). B, fixed normal myometrium and leiomyoma tissue from Tsc2
Ek /+ rats were analyzed by immunohistochemistry with an anti-p27 antibody. Representative images [magnification, Â20 (right); Â40 (middle and left)]. Arrowheads, nuclear p27 immunoreactivity in normal myometrium. C, cytosolic (C ) and nuclear (N ) lysates generated from Tsc2 +/+ and Tsc2 À/À MEFs were analyzed by immunoblotting with anti-p27 and anti-Sp1 antibodies. Sp1 was analyzed as a control for fractionation (left ). Kidney tissues from Tsc2 +/À mice containing both normal (N ) and tumor (T ) tissues were analyzed by immunohistochemistry with an anti-p27 antibody. Representative images (magnification, Â20; right ).
Immunocytochemistry/immunohistochemistry. Cells either transfected or treated as indicated were fixed followed by permeabilization. Cells were stained with mouse anti-p27, rabbit anti-hemagglutinin (HA; Santa Cruz Biotechnology), and mouse anti-Flag (Sigma) antibodies. Secondary antibodies were conjugated with FITC (Abcam; goat anti-mouse or goat anti-rabbit) or Texas red (Jackson ImmunoResearch Laboratories; donkey anti-mouse). For endogenous p27 staining, slides were blocked with the Endogenous Avidin/Biotin Blocking Kit (Zymed) before applying the primary antibody. Primary antibodies were recognized with biotin-conjugated donkey anti-mouse (Abcam) and streptavidin-conjugated FITC or Texas red (Molecular Probes). The VectaShield mounted coverslips were visualized by conventional microscopy with a fluorescent attachment (Olympus). MagnaFire version 2.1 C (Olympus) software was used for image acquisition.
For immunohistochemistry, fixed tissues were incubated with an anti-p27 antibody, recognized with a horseradish peroxidase-conjugated antimouse antibody. Slides were stained with 3,3 ¶-diaminobenzidine and visualized by conventional microscopy.
In vitro kinase assays. GST-p27 fusion proteins were induced and purified using BL21-Star cells, followed by cleavage from GST using PreScission Protease (f32-units; Amersham Pharmacia Biotech). Purified recombinant p27 protein was analyzed by SDS-PAGE and quantitated with a BCA Protein Quantitation kit (Pierce). AMPK (10 milliunits; Upstate) was incubated with 1 Ag of the indicated recombinant p27 protein for 15 min at 30jC. The reactions were then separated by SDS-PAGE, dried, and visualized.
For Cdk2 kinase assays, lysates were immunoprecipitated overnight at 4jC Apoptosis assays. For terminal deoxyribonucleotidyl transferasemediated dUTP nick end labeling (TUNEL) staining, formalin-fixed paraffin sections were processed and stained using a FragEl DNA fragmentation kit (Calbiochem). Five tumor fields (20Â) from kidneys of 5-to 6-mo-old Tsc2 +/À /p27 mice were scored blinded to genotype for TUNEL immunoreactivity by a board-certified pathologist. The total number of tumor-bearing animals scored for each genotype was Tsc2 
Results

Elevated AMPK signaling correlates with cytoplasmic localization of p27 in Tsc2
À/À cells and tumors. Eker rats are heterozygous for the Tsc2 tumor suppressor gene (Tsc2 Ek/+ ) and develop uterine leiomyoma subsequent to loss of the wild-type Tsc2 allele with a high frequency (23) . We examined a uterine tumor-derived cell line, ELT-3 (20) , and uterine tumors from Eker rats for localization of p27. Endogenous p27 was detected only in the cytosolic fraction of ELT-3 cells grown in the absence or presence of serum, and immunocytochemistry revealed diffuse cytoplasmic staining without nuclear concentration of p27 in these cells (Fig. 1A) . Additionally, even when a Flag-tagged wildtype p27 construct (Flag-p27-WT) was overexpressed in ELT-3 cells, the vast majority of exogenous p27 was retained in the cytosolic fraction of these cells ( Supplementary Fig. S1A ). In contrast, in NIH3T3 (Tsc2 +/+ ) cells, endogenous p27 was detected in both the nuclear and cytosolic fractions and immunocytochemistry showed concentrated nuclear staining of endogenous p27 (Fig. 1A) . Immunohistochemistry analyses of uterine leiomyomas from Eker rats also revealed an aberrant cellular localization pattern of p27. p27 was detected solely in nuclei of normal myometrial cells (Fig. 1B , left and middle), whereas more than half of the tumors (13 of 22) had strong cytoplasmic p27 immunoreactivity accompanied by nuclear staining (Fig. 1B , middle) and f20% (5 of 22) had predominantly cytoplasmic p27 with little or no nuclear reactivity (Fig. 1B, right) . Fewer than 20% (4 of 22) were negative for p27 or had predominantly nuclear staining.
Furthermore, we examined p27 localization in Tsc2 À/À MEFs and in microscopic kidney lesions of Tsc2 +/À mice predisposed to develop renal cell carcinoma following spontaneous loss of the wild-type Tsc2 allele (19) . p27 was primarily detected in the cytosolic fraction of Tsc2 À/À MEFs, whereas p27 was localized to both the cytosolic and nuclear fractions of MEFs derived from Tsc2 +/+ mice (Fig. 1C) . Moreover, p27 was readily detectable in the cytoplasm of microscopic kidney lesions from compound A, left, whole-cell lysates from Tsc2 +/+ and Tsc2 À/À MEF cells were immunoblotted with an antibody that recognizes phosphorylated AMPK-a at T172 (p-AMPK-a) and an anti-AMPK-a antibody. AMPK-a levels were analyzed as a control for equal loading. Right, whole-cell lysates from ELT-3 cells and HEK293 cells were immunoblotted with anti-p-AMPK-a (T172), anti-AMPK-a, anti-p-ACC (S79), and anti-ACC antibodies. Both AMPK-a levels and ACC levels were analyzed as controls for equal loading. B, protein lysates from normal uterine tissue (myometrium) and three independent uterine tumors from Eker rats (Tsc2 Ek/+ ) were normalized and immunoblotted with anti-tuberin, anti-p27, anti-p-AMPK-a (T172), anti-AMPK-a, anti-AMPK-a1, anti-AMPK-a2, anti-p-S6, and anti-S6 antibodies.
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We also evaluated AMPK signaling, which, similar to the observation from Hay's group (16) , was elevated in Tsc2 À/À MEFs as indicated by increased phosphorylation of AMPK-a at T172 (Fig. 2A) . ELT-3 cells also exhibited characteristic downregulation of AKT due to a negative feedback from elevated mTOR signaling (Supplementary Fig. S1B ) and elevated AMPK signaling as indicated by both AMPK-a phosphorylation and increased phosphorylation of ACC at S79, a direct target of AMPK ( Fig. 2A) . Because ELT-3 cells exhibited increased AMPK signaling and cytoplasmic localization of p27, we examined primary uterine leiomyomas from Eker rats for activation of the AMPK signaling pathway. Similar to ELT-3 cells, uterine leiomyomas from Eker rats exhibited elevated phospho-S6 levels characteristic of elevated mTOR signaling associated with loss of tuberin function in these tumors ( Fig. 2B; Supplementary  Fig. S1B; ref. 23 ). Both AMPK-a1 and AMPK-a2 could be detected in uterine leiomyomas and normal myometrium of Eker rats, with similar p27 protein levels (Fig. 2B) . However, uterine leiomyomas from Eker rats exhibited increased levels of phosphorylated AMPK-a at T172 as well as a slower migrating form of phosphorylated AMPK-a and total AMPK-a compared with normal myometrium from Eker rats (Fig. 2B) . These data led us to explore a possible linkage between AMPK signaling and altered p27 localization.
AMPK signaling regulates cytoplasmic localization of p27. To investigate whether AMPK signaling could alter the subcellular localization of p27, we modulated AMPK activity in both tuberindeficient and tuberin-proficient cells to determine the effect of AMPK on p27 localization. Initially, ELT-3 cells (with constitutively active AMPK and cytoplasmic p27) were treated with pharmacologic inhibitors of the LKB1/AMPK signaling pathway, H-89 and Compound C, and p27 localization was observed by immunocytochemistry. H-89 has been reported to inhibit PKAmediated phosphorylation of LKB1 (24) and to counteract certain . Right, detection of p27 in the nucleus, cytoplasm, or both compartments was scored as a percentage of total cells analyzed. B, tuberin-expressing NIH3T3 cells were grown in media without serum in the presence or absence of glucose. Cells were then used to generate whole-cell (W ), cytosolic (C ), and nuclear (N ) lysates. Top left, cytosolic and nuclear lysates were immunoblotted with anti-p27 and anti-Sp1 antibodies. Bottom left, whole-cell lysates were analyzed by immunoblotting with anti-p27, anti-p-AMPK-a (T172), and anti-p-ACC (S79) antibodies. Both p27 levels and levels of a nonspecific band (L.C. ) indicate equal loading. Right, NIH3T3 cells grown in the presence or absence of glucose were also analyzed by immunocytochemistry with an anti-p27 antibody. Representative images (original magnification, Â40). C, tuberin-expressing NIH3T3 cells were transfected with Flag-p27-WT alone or in combination with HA-tagged WT-AMPK-a1, CA-AMPK-a1, or DN-AMPK-a1. Cells were then analyzed by immunocytochemistry with anti-Flag and anti-HA antibodies, and the percentage of cells expressing HA in which exogenous p27 was detected solely in the nucleus was determined. Statistical analysis (Fischer test) showed a significant decrease in the percentage of cells with nuclear Flag-p27-WT when CA-AMPK-a1 was overexpressed (a, P < 0.0001) and a significant increase in the percentage of cells with nuclear Flag-p27-WT when DN-AMPK-a1 was overexpressed (b, P < 0.0001). . T170 is a primary determinant of p27 localization in response to AMPK signaling. A, schematic of p27 showing conservation of amino acid residues at S83, T170, and T197. A table with potential AMPK phosphorylation sites and surrounding amino acid sequences from several species is shown below. B, in vitro kinase assays were performed with AMPK using equal amounts of WT p27 in the absence or presence of AMP or p27 mutated at potential AMPK phosphorylation sites in the presence of AMP. The amount of 32 P incorporated into each of the p27 proteins was detected by autoradiography and normalized to p27-WT. A graph depicting the relative amount of phosphorylation is shown below. C, NIH3T3 cells were transfected with plasmids encoding Flag-p27-WT, Flag-p27-S83A, Flag-p27-T197A, Flag-p27-T170A, or Flag-p27-T170D and then analyzed by immunocytochemistry with an anti-Flag antibody. The percentage of cells with either nuclear staining (black columns ) or cytoplasmic staining (white columns ) was determined by immunocytochemistry with an anti-Flag antibody. Statistical analysis (Fischer test) showed a significant change in localization when comparing either T170A or T170D mutants to WT (a, P = 0.0147 and P = 0.0067, respectively) and when comparing T170A to T170D (b, P < 0.0001). D, NIH3T3 cells were transiently transfected with Flag-p27-WT, Flag-p27-S83A, Flag-p27-T170A, or Flag-p27-T197A plasmids in combination with the HA-CA-AMPK-a1 plasmid. Cells were then analyzed by immunocytochemistry with anti-Flag and anti-HA antibodies, and the percentage of cells with CA-AMPK-a1 in which Flag-p27 was detected in the nucleus was quantified. Statistical analysis (Fischer test) showed a significant difference between cells transfected with Flag-p27-T170A and Flag-p27-WT when expressed along with CA-AMPK-a1 (a, P < 0.0001). Right, representative images of immunocytochemistry with anti-HA (CA-AMPK-a1) and anti-Flag antibodies (Flag-p27 ).
Cancer Res 2008; 68: (16 (25) , whereas Compound C is a direct AMPK inhibitor (26) . As shown in Fig. 3A , the percentage of cells with nuclear p27 staining increased whereas the percentage of cells with cytoplasmic p27 staining decreased following a 5-hour treatment with either H-89 or Compound C. Additionally, subcellular fractionation confirmed nuclear relocalization of p27 in ELT-3 cells following a 3-hour treatment with H-89 (data not shown).
AMPK activity was also modulated in tuberin-proficient NIH3T3 cells by glucose deprivation, which activates AMPK. Glucose deprivation of NIH3T3 cells in the presence or absence of serum caused an increase in AMPK signaling as determined by increased phosphorylation of AMPK-a (T172) and ACC (S79; Fig. 3B ). Additionally, glucose deprivation led to cytosolic retention of p27 and diffuse cytoplasmic staining without nuclear retention of p27, as revealed by both subcellular fractionation and immunocytochemistry (Fig. 3B) . Furthermore, the PI3K and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase/ERK inhibitors LY294002 and PD98059 had no effect on p27 localization or phospho-AMPK-a levels while blocking their respective targets in glucose-deprived NIH3T3 cells (Supplementary Fig. S2 ).
Finally, Flag-p27-WT was transiently coexpressed with HAtagged wild-type AMPK-a1 (WT-AMPK-a1), constitutively active AMPK-a1 (CA-AMPK-a1), or dominant negative AMPK-a1 (DN-AMPK-a1) in NIH3T3 cells to further determine whether AMPK signaling altered p27 localization. Exogenous Flag-p27-WT exhibited concentrated nuclear staining in f40% of cells when overexpressed alone or in 30% of cells that coexpressed WT-AMPKa1 (Fig. 3C) . However, <10% of cells overexpressing CA-AMPK-a1 showed concentrated nuclear staining of Flag-p27-WT whereas cells that expressed DN-AMPK-a1 showed concentrated nuclear staining of Flag-p27-WT in >70% cells (Fig. 3C) . Taken together, these data indicate that AMPK signaling regulates localization of p27 both in the presence and absence of growth factors and that regulation of p27 localization is AMPK dependent in both tuberinproficient and tuberin-deficient cells.
T170 mediates cytoplasmic localization of p27 in response to AMPK signaling. Using AMPK target recognition consensus sequences, we identified three potential AMPK recognition sequences in p27 that are highly conserved across multiple species: S83, T170, and T197 (Fig. 4A ). Of these, the human terminal threonine (T198) has previously been shown to be phosphorylated by AMPK (17) . We conducted in vitro kinase assays to determine MEFs grown to 100% confluency (left ) or in the absence of serum (right ) were used for immunoprecipitation of Cdk2. In vitro kinase assays were then performed with Cdk2 immunoprecipitates with histone H1B as a substrate, and incorporation of 32 P into histone H1B was detected by autoradiography and quantified (top graphs ). Immunoprecipitates were also analyzed by immunoblotting with an anti-Cdk2 antibody to ensure that equal amounts of Cdk2 were used in kinase assays (bottom ). B, ELT-3 cells were treated with 20 Amol/L Compound C for the indicated times and used to generate whole-cell lysates. Lysates were analyzed by immunoblotting with anti-p27 and anti-Cdk2 antibodies or used for immunoprecipitation of Cdk2. Immunoprecipitates were used for in vitro kinase assays using histone H1B as a substrate or analyzed by immunoblotting with an anti-Cdk2 antibody to ensure that equal amounts of Cdk2 were used in kinase assays. Incorporation of 32 P into histone H1B was detected by autoradiography. C, ELT-3 cells were transiently transfected with Flag-p27-WT and Flag-p27-T170A. Whole-cell lysates were analyzed by immunoblotting with anti-p27 antibody or used for immunoprecipitation of Cdk2. Immunoprecipitates were used for in vitro kinase assays with histone H1B as a substrate or analyzed by immunoblotting with an anti-Cdk2 antibody. Incorporation of 32 P into histone H1B was detected by autoradiography and the kinase activity from two independent experiments was measured by densitometric analysis. Statistical analysis (t test) showed a significant decrease in the kinase activity of cells overexpressing Flag-p27-T170A (P = 0.05).
whether AMPK could phosphorylate murine p27 at one or more of these residues. AMPK phosphorylated recombinant murine wildtype p27 (p27-WT) in vitro and exhibited a 5-fold increase in phosphorylation in the presence of AMP (Fig. 4B) . A 20% to 35% reduction in p27 phosphorylation was observed when serine/ threonine was mutated to alanine at S83, T170, or T197 compared with p27-WT, and all three mutations in combination led to a >50% reduction in p27 phosphorylation (Fig. 4B) . These data suggest that AMPK can directly phosphorylate p27 directly at T170, the COOHterminal threonine residue (hT197/mT198), and potentially other sites such as S83 as well.
We next investigated whether mutations of these potential AMPK target sites could alter localization of p27. Alanine substitution of T170 (Flag-p27-T170A) or mutation to a phosphomimetic residue (Flag-p27-T170D) significantly changed p27 localization, from 40% nuclear p27 in Flag-p27-WT-expressing cells to >50% and f20% in case of Flag-p27-T170A and Flagp27-T170D, respectively (Fig. 4C) . Mutation of S83 (Flag-p27-S83A) or T197 (Flag-p27-T197A) to alanine did not alter localization of p27 (Fig. 4C) . Additionally, Flag-p27-T170A exhibited concentrated nuclear staining (f40% cells) when coexpressed with CA-AMPK-a1. In contrast, nuclear Flag-p27-WT, Flag-p27-S83A, or Flag-p27-T197A staining was significantly lower than Flag-p27-T170A (<20%) in the presence of CA-AMPK-a1 (Fig. 4D) . These data indicate that T170 is a primary determinant of p27 localization when AMPK signaling is active and contributes to retention of p27 in the cytoplasm.
Tuberin-null cells have elevated Cdk2 activity that is reduced by inhibition of AMPK signaling. To identify a possible functional consequence of cytoplasmic localization of p27 in tuberin-null cells, we examined Cdk2 activity in both Tsc2 +/+ cells and Tsc2
À/À cells under conditions in which growth and Cdk2 activity are normally repressed. Cdk2 activity from Tsc2 À/À MEFs was 4-fold higher than Cdk2 activity of Tsc2 +/+ MEFs when cells were at 100% confluency, and >40-fold greater when cells were deprived of serum (Fig. 5A) .
Because Cdk2 kinase activity was high in ELT-3 cells with activated AMPK and cytosolic p27 (Fig. 5B) , we sought to determine whether inhibition of AMPK signaling (and relocalization of p27 to the nucleus) would inhibit Cdk2 kinase activity. ELT-3 cells treated with Compound C for 5 or 24 h, which relocalized p27 to the nucleus (Fig. 3A) and inhibited AMPK activity, exhibited lower Cdk2 kinase activity than nontreated cells (Fig. 5B) . These data suggest that exclusion of p27 from the nucleus is associated with elevated Cdk2 kinase activity, which can be reduced by relocalization to the nucleus. Additionally, as shown in Fig. 5C , Flag-p27-T170A (which is retained in the nucleus; Fig. 4D ) was more efficient at inhibiting Cdk2 kinase activity in ELT-3 cells compared with Flag-p27-WT, which is mislocalized to the cytoplasm in these cells. Thus, cytoplasmic sequestration of p27 inhibits the ability of this Cdk inhibitor to repress Cdk2 activity.
p27 localization mediates the antiapoptotic function of AMPK. Another possible functional consequence of cytoplasmic localization of p27 due to elevated AMPK signaling is resistance to apoptosis, and we have recently shown that p27 mediates a decision to undergo apoptosis or autophagy in tumor cells (17) . Defects in AMPK activation have previously been linked to increased sensitivity to cell death (27) , and cytosolic p27 has been reported to inhibit apoptosis on serum deprivation (28) . To investigate a potential linkage between AMPK signaling, cytoplasmic p27, and apoptosis, NIH3T3 cells and Tsc2 +/+ MEFs (with low levels of activated AMPK and nuclear p27) or tuberin-null ELT-3 cells and Tsc2 À/À MEFs (with high levels of activated AMPK and cytoplasmic p27) were deprived of serum, and apoptosis was measured both before and after serum starvation by quantifying the percentage of nuclei exhibiting bright 4 ¶,6-diamidino-2-phenylindole (DAPI) staining or nuclear fragmentation. As shown in Fig. 6A , both NIH3T3 cells and Tsc2 +/+ MEFs exhibited an increase in the percentage of nuclei with apoptotic features 24 hours after removal of serum. Whereas both Tsc2 À/À MEFs and ELT-3 cells had a high background level of apoptotic nuclei when grown in serum, removal of serum failed to increase the percentage of nuclei with apoptotic features in tuberin-null ELT-3 cells or Tsc2 À/À MEFs (Fig. 6A) . Apoptosis was also quantified by measuring caspase-3/ caspase-7 activity following 5, 10, and 20 hours of serum starvation. Both NIH3T3 cells and Tsc2 +/+ MEFs exhibited >15-fold increase in caspase activity as early as 5 hours after serum removal, which was sustained throughout the 20-hour time course (Fig. 6B) . ELT-3 cells and Tsc2
À/À MEFs with cytoplasmic p27 exhibited dramatically lower caspase activity than NIH3T3 cells and Tsc2 +/+ MEFs with primarily nuclear localized p27 at all time points of serum withdrawal, although Tsc2 À/À MEFs and ELT-3 cells did eventually exhibit a slight increase in caspase activity after 20 hours of serum withdrawal (Fig. 6B) . Similarly, in p27 À/À MEFs and p27 +/+ MEFs, the absence of p27 correlated with increased sensitivity to apoptosis. Serum starvation for 24 hours led to a >13-fold increase in caspase activity in p27 À/À MEFs that express a truncated p27
protein lacking the NH 2 -terminal nuclear export signal (29) , resulting in its nuclear retention (data not shown), whereas p27
MEFs were refractory to the induction of apoptosis (Fig. 6B ), which correlated with high levels of cytosolic p27 in these cells (data not shown). These correlative data showed that cells with activated AMPK and cytoplasmic p27 are resistant to the induction of apoptosis by serum deprivation. To determine whether there was a direct link between AMPK activation, cytoplasmic localization of p27, and resistance to apoptosis, NIH3T3 cells were deprived of glucose before serum starvation. Glucose deprivation (which activates AMPK and sequesters p27 in the cytoplasm, Fig. 3B ) markedly delayed caspase activation induced by serum starvation up to 20 hours in these cells (Fig. 6B) . In addition, ELT-3 cells and Tsc2 À/À MEFs were treated with Compound C to determine whether inhibition of AMPK signaling and altered localization of p27 (Figs. 3A and 6C) could alter susceptibility to apoptosis in these cells. Treatment with Compound C led to an increase in caspase activation after 5 hours (Fig. 6C ) or 20 hours (data not shown) of serum deprivation. These data indicate that modulation of AMPK signaling and p27 localization alters susceptibility to apoptosis, whereas inhibition of AMPK activity induces an apoptosis-sensitive phenotype that is correlated with a loss of cytoplasmic p27.
To investigate a potential linkage between p27 and resistance to apoptosis in tuberin-null tumors, Tsc2 +/À mice predisposed to renal tumorigenesis (19, 30) were crossed with p27 +/À mice, which develop tumors at sites other than the kidney with a short latency (18) . Tsc2 Table  S1 ) was different in p27-proficient (p27 +/+ ) versus p27-deficient (p27 +/À or p27 À/À ) animals, which was interesting given that p27 deficiency predisposes to tumors at several other organ sites. However, the apoptotic index was significantly higher in tumors that developed in p27-deficient animals (Tsc2 +/+ mice; Fig. 6D ). This finding was consistent with the antiapoptotic activity of p27 observed in Tsc2-null cells in vitro (Fig. 6A-C) , and may underlie the observation that p27 deficiency did not significantly increase renal tumor development in Tsc2 +/À mice.
Discussion
We found that tuberin-null cell lines and tumors exhibit activated AMPK signaling and cytoplasmic localization of p27. Furthermore, we showed that activation of AMPK signaling causes cytoplasmic localization of p27 in both tuberin-proficient and tuberin-deficient cells and that T170 of p27 can be phosphorylated by AMPK in vitro and regulates p27 localization in response to AMPK signaling. We also found that cells with activated AMPK and cytoplasmic p27 had elevated Cdk2 activity that could be inhibited by inactivating AMPK and relocalizing p27 to the nucleus. Lastly, we found that elevated AMPK signaling and cytoplasmic p27 promoted resistance to apoptosis, which could be reversed by inhibition of AMPK signaling and decreasing levels of cytoplasmic p27.
We have shown that tuberin-null cells and tumors from Eker rats have elevated AMPK signaling, confirming a previous report showing that AMPK signaling is elevated in Tsc2 À/À MEFs (16).
One possible mechanism for activated AMPK signaling in tuberinnull cells is decreased IRS1 and AKT activity due to the negative feedback from S6K to IRS1 in tuberin-null cells (Supplementary data and refs. 4-6) because AKT signaling reportedly antagonizes AMPK activity (16, 31) . Alternatively, the elevation of reactive oxygen species associated with loss of either Tsc1 or Tsc2 (32, 33) in cells and tumors could also contribute to elevated AMPK signaling because AMPK has been shown to be redox sensitive (34) . Previous studies have linked tuberin with p27 stabilization and localization (13, 15, 35) . p27 was reported to be more unstable in tuberin-null cells and mislocalized to the cytosol, and overexpression of Tsc2 was reported to increase p27 protein levels (15, 35) . In addition, tuberin was reported to interact with p27 and increase nuclear p27 by regulating the interaction between AKTphosphorylated p27 and 14-3-3 (13). However, tuberin-null cell lines and tumors exhibit decreased IRS1 and AKT activity due to the aforementioned negative feedback from S6K to IRS1 (data not shown and refs. [4] [5] [6] . Therefore, an AKT-dependent mechanism, as proposed by Rosner and colleagues (13) , is unlikely to be responsible for mislocalization of p27 in tuberin-null cells and tumors. Our study provides an alternative mechanism in which the relationship between Tsc2 and p27 and subcellular localization of this Cdk inhibitor can be understood in the context of activated AMPK signaling.
Localization of p27 is a complex process that is affected by phosphorylation at multiple residues (36) . For example, phosphorylation of p27 at S10 by hKIS leads to its cytoplasmic localization and degradation, whereas phosphorylation at S10 by the Mirk/ dyrk1B kinase does not alter p27 localization (36) . Additionally, phosphorylation of human p27 at T157/T198 by AKT or phosphorylation at T198 by ribosomal S6 kinase also alters subcellular localization of p27 through stabilization and interaction with 14-3-3 proteins (10, 36) . S10 of p27 is not a potential AMPK target site, and T157 of p27 is not a conserved amino acid residue in rodents. Moreover, modulation of AKT or ribosomal S6 kinase signaling had no effect on p27 localization (Supplementary data), and similar to our data, mutation of T198 had no effect on p27 localization in a report showing that AMPK phosphorylates this residue on p27 (17) . Instead, we found that T170, a conserved putative AMPK target site near the p27 nuclear localization signal, was a primary determinant of murine p27 localization in response to AMPK signaling, and this site was phosphorylated by AMPK in vitro. This is the first report to identify T170 as a site regulating localization of p27, although it is not clear at this time if AMPK directly phosphorylates p27 at T170 in vivo.
Cytosolic localization of p27 sequesters p27 from Cdk proteins in the nucleus. Previous reports have shown that Cdk2 activity is elevated in Tsc2 À/À EEF8 cells, and this activity can be inhibited by addition of recombinant p27 (15) . We found that Cdk2 activity was elevated in Tsc2 À/À MEFs and tuberin-null ELT-3 cells, and that inhibition of AMPK signaling decreased Cdk2 activity in tuberin-null cells. Moreover, we confirmed that p27 localization regulated Cdk2 kinase activity. These data suggest that elevated Cdk2 activity may be a consistent feature of tuberin-null tumors in the context of TSC, warranting additional analysis in TSCassociated tumors, with the goal of potentially targeting Cdk2 therapeutically.
In addition, a recent report indicates that cytoplasmic p27 can prevent apoptosis and promote tumorigenicity (28) . In fact, transgenic mice expressing p27 that cannot inhibit Cdk2 develop tumors in multiple tissues, and p27 is localized to the cytoplasm in lung tumors from these mice (37) . These data are consistent with our observations that kidney lesions that developed in Tsc2 +/À / p27 +/+ mice had lower apoptotic indices than lesions that developed in Tsc2 +/À /p27 +/À or Tsc2 +/À /p27 À/À mice. We observed that resistance to apoptosis in response to serum deprivation correlated with activated AMPK signaling and cytoplasmic localization of p27, and that resistance to apoptosis on serum starvation in tuberin-null cell lines could be overcome by inhibition of AMPK signaling and reduction in cytoplasmic p27. Tsc2
À/À
MEFs were previously shown to undergo apoptosis on serum starvation as measured by caspase cleavage in both Tsc2 À/À and Tsc2 +/+ MEFs, although the relative amount of apoptosis occurring in these cells was not quantitated (6) . Our data indicate that although caspase activity is increased on serum deprivation of both Tsc2 +/+ and Tsc2 À/À cells, the relative caspase activity is much higher in Tsc2 +/+ cells. Interestingly, Inoki and colleagues (38) have previously examined apoptosis in response to energy depletion. In these studies, Tsc2-deficient cells (LEF and EEF8 cell lines) were sensitive to induction of apoptosis in response to 2-deoxyglucose, as were Tsc1 À/À MEFs. However, EEF8 cells have previously been characterized as having diminished p27 levels (15) , and the response of Tsc2 À/À MEFs to energy depletion was not examined in their study. Thus, it seems that the relationship of AMPK activity, p27 localization, and resistance to apoptosis in Tsc1/Tsc2-null cells is likely complex and will be affected by both the cell background and apoptotic stimuli used. Importantly, many targeted therapies, such as receptor tyrosine kinase inhibitors and antiangiogenic agents, could activate AMPK in tumors via induction of hypoxia and/or nutrient deprivation. In tumors that express p27, altered localization of p27 and repression of apoptosis is a potential adverse effect that could occur as a result of therapy-induced AMPK activation. Therefore, further studies of the relationship between p27 localization, AMPK signaling, and resistance to apoptosis in tumors will allow us to better understand how p27 localization may modulate response to therapy and to gain greater insight into the duality of p27 as a regulator of both the cell cycle and cell death.
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